Compare OFIX & PEPG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | OFIX | PEPG |
|---|---|---|
| Founded | 1987 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 500.2M | 440.0M |
| IPO Year | 1998 | 2022 |
| Metric | OFIX | PEPG |
|---|---|---|
| Price | $12.03 | $6.15 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 6 |
| Target Price | ★ $17.25 | $11.67 |
| AVG Volume (30 Days) | 274.2K | ★ 618.9K |
| Earning Date | 05-18-2026 | 06-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 29.39 | 25.61 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $822,312,000.00 | N/A |
| Revenue This Year | $6.32 | N/A |
| Revenue Next Year | $6.01 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 2.85 | N/A |
| 52 Week Low | $10.25 | $0.89 |
| 52 Week High | $17.00 | $7.80 |
| Indicator | OFIX | PEPG |
|---|---|---|
| Relative Strength Index (RSI) | 29.82 | 51.50 |
| Support Level | $10.55 | $4.36 |
| Resistance Level | $16.50 | $6.81 |
| Average True Range (ATR) | 0.58 | 0.55 |
| MACD | -0.08 | -0.04 |
| Stochastic Oscillator | 6.71 | 55.11 |
Orthofix Medical Inc. is a medical device company delivering orthopedic and spine solutions to healthcare providers. The company has two reportable segments: Global Spine and Global Limb Reconstruction. The Global Spine segment offers bone growth therapies, spinal implants, biologics, and enabling technologies used in spinal procedures. The Global Limb Reconstruction segment provides products and solutions for limb deformity correction, limb lengthening, fracture management, and limb preservation, supported by digital technologies. It generates the majority of its revenue from the Global Spine segment.
PepGen Inc is a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapeutics to transform the treatment of severe neuromuscular and neurologic diseases. The company has developed its Enhanced Delivery Oligonucleotide platform to improve the uptake and activity of conjugated oligonucleotide therapeutics. Its EDO peptides are engineered to optimize tissue penetration, cellular uptake, and nuclear delivery, and in preclinical studies, it is observed their ability to transport oligonucleotides into a broad range of target tissues, including smooth, skeletal, and cardiac muscle and the central nervous system. Its pipeline products are; PGN-EDO51, PGN-EDODM1, and others including PGN-EDO53 and PGN-EDO45.